May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Additivity of Brinzolamide vs. Brimonidine 0.15% to Travoprost 0.004%
Author Affiliations & Notes
  • R.M. Feldman
    Univ of Texas Houston Med Sch, Houston, TX
    Ophthalmology–Hermann Eye Ctr,
  • T.C. Prager
    Univ of Texas Houston Med Sch, Houston, TX
    Ophthalmology,
  • L. Baker
    Ophthalmology, Hermann Eye Center, Houston, TX
  • A.Z. Chuang
    Univ of Texas Houston Med Sch, Houston, TX
    Ophthalmology,
  • Additivity Study Group
    Univ of Texas Houston Med Sch, Houston, TX
  • Footnotes
    Commercial Relationships  R.M. Feldman, Alcon, Allergan,Pfizer, Merck, F; Alcon, Allergan,Pfizer, Merck, C; Alcon, Allergan, Pfizer, Merck, R; T.C. Prager, None; L. Baker, None; A.Z. Chuang, None.
  • Footnotes
    Support  NEI Core Grant 10608, Research to Prevent Blindness, Alcon Investigtor Initiated Grant, Hermann Eye Fund
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 435. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R.M. Feldman, T.C. Prager, L. Baker, A.Z. Chuang, Additivity Study Group; Additivity of Brinzolamide vs. Brimonidine 0.15% to Travoprost 0.004% . Invest. Ophthalmol. Vis. Sci. 2006;47(13):435.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Introduction:
 

Glaucoma is treated with IOP lowering medications or surgery to reduce the risk of visual field loss. The current treatment regimen often begins with a prostaglandin. If IOP lowering is insufficient, a second drug is frequently added. Topical carbonic anhydrase inhibitors and α2 agonists are common choices. There are few citations on the additive effect of the drugs to prostaglandins.

 
Purpose:
 

To compare the additive effect on IOP of adding brinzolamide 1% BID or brimonidine 0.15% BID to travoprost 0.004% in patients with primary open angle glaucoma, pseudoexfoliation or ocular hypertension. Main Outcomes Measures: ANCOVA baseline adjusted mean decrease in diurnal IOP to month 3, Adjusted mean IOP at 8 AM (prior to dosing), 12 Noon, 4 PM and diurnal at month 3.

 
Methods:
 

Double masked randomized parallel group, 17 center trial. After travoprost 0.004% QHS run in, subjects were randomized to receive brinzolamide 1% or brimonidine 0.15% BID in addition to travoprost and were followed at 1 and 3 months.

 
Results:
 

163 subjects were randomized and 151 evaluable. Adjusted mean (+/– SEM) reductions in diurnal IOP from baseline to month 3 were 2.9+/– 0.26 mmHg in the brinzolamide group, versus 2.1 +/– 0.26 mmHg in patients receiving brimonidine (p=0.035). Computed power to detect a difference of 1.5 mm Hg with a beta of 0.8 and alpha of 0.05 was 0.98. Both treatments were well tolerated with few withdrawals.

 
Conclusions:
 

Adding brinzolamide to travoprost lowers IOP more than adding brimonidine at 8 AM, 4 PM, and diurnal.  

 
Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • intraocular pressure • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×